JP2023517636A - 炎症性腸疾患を治療するための方法ｉ - Google Patents

炎症性腸疾患を治療するための方法ｉ Download PDF

Info

Publication number
JP2023517636A
JP2023517636A JP2022554671A JP2022554671A JP2023517636A JP 2023517636 A JP2023517636 A JP 2023517636A JP 2022554671 A JP2022554671 A JP 2022554671A JP 2022554671 A JP2022554671 A JP 2022554671A JP 2023517636 A JP2023517636 A JP 2023517636A
Authority
JP
Japan
Prior art keywords
subject
cells
disease
endoscopic
clinical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022554671A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023517636A5 (enExample
Inventor
シルヴィウ・イテスク
Original Assignee
メゾブラスト・インターナショナル・エスアーエールエル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020900742A external-priority patent/AU2020900742A0/en
Application filed by メゾブラスト・インターナショナル・エスアーエールエル filed Critical メゾブラスト・インターナショナル・エスアーエールエル
Publication of JP2023517636A publication Critical patent/JP2023517636A/ja
Publication of JP2023517636A5 publication Critical patent/JP2023517636A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2022554671A 2020-03-11 2021-03-11 炎症性腸疾患を治療するための方法ｉ Pending JP2023517636A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020900742A AU2020900742A0 (en) 2020-03-11 Method for treating inflammatory bowel disease I
AU2020900742 2020-03-11
PCT/EP2021/056191 WO2021180850A1 (en) 2020-03-11 2021-03-11 Method for treating inflammatory bowel disease i

Publications (2)

Publication Number Publication Date
JP2023517636A true JP2023517636A (ja) 2023-04-26
JP2023517636A5 JP2023517636A5 (enExample) 2024-03-13

Family

ID=74884937

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022554671A Pending JP2023517636A (ja) 2020-03-11 2021-03-11 炎症性腸疾患を治療するための方法ｉ

Country Status (9)

Country Link
US (1) US20230172991A1 (enExample)
EP (1) EP4117691A1 (enExample)
JP (1) JP2023517636A (enExample)
KR (1) KR20220152239A (enExample)
CN (1) CN115361957A (enExample)
AU (1) AU2021234104A1 (enExample)
BR (1) BR112022017560A2 (enExample)
CA (1) CA3170915A1 (enExample)
WO (1) WO2021180850A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023517641A (ja) * 2020-03-11 2023-04-26 メゾブラスト・インターナショナル・エスアーエールエル 炎症性腸疾患を治療するための方法ｉｉ

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120087868A1 (en) 2010-10-08 2012-04-12 Gabriele Todd Nanoparticle-loaded cells
SG11202004680UA (en) 2017-11-22 2020-06-29 Mesoblast Int Sarl Cellular compositions and methods of treatment i

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009057537A1 (ja) * 2007-11-02 2009-05-07 Jcr Pharmaceuticals Co., Ltd. ヒト間葉系幹細胞含有医薬組成物
JP2023517641A (ja) * 2020-03-11 2023-04-26 メゾブラスト・インターナショナル・エスアーエールエル 炎症性腸疾患を治療するための方法ｉｉ

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US6251295B1 (en) 1998-01-08 2001-06-26 Nexell Therapeutics Inc. Method for recirculation washing of blood cells
CN104873542A (zh) * 2015-05-21 2015-09-02 北京青藤谷禧干细胞科技研究院有限公司 一种脐带间充质干细胞注射液及其制备方法和应用
GB201604304D0 (en) * 2016-03-14 2016-04-27 Tigenix S A U Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
WO2018002930A1 (en) * 2016-06-30 2018-01-04 Stem Cell Medicine Ltd. Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
WO2018182612A1 (en) * 2017-03-30 2018-10-04 Progenity Inc. Methods and ingestible devices for the regio-specific release of stem cells at the site of gastrointestinal tract disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009057537A1 (ja) * 2007-11-02 2009-05-07 Jcr Pharmaceuticals Co., Ltd. ヒト間葉系幹細胞含有医薬組成物
JP2023517641A (ja) * 2020-03-11 2023-04-26 メゾブラスト・インターナショナル・エスアーエールエル 炎症性腸疾患を治療するための方法ｉｉ

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GASTROENTEROLOGY, vol. 154, JPN6025008832, 2018, pages 1334 - 1342, ISSN: 0005546908 *
INTERNATIONAL JOURNAL OF STEM CELLS, vol. 11, no. 1, JPN6025008831, 2018, pages 39 - 47, ISSN: 0005546909 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023517641A (ja) * 2020-03-11 2023-04-26 メゾブラスト・インターナショナル・エスアーエールエル 炎症性腸疾患を治療するための方法ｉｉ

Also Published As

Publication number Publication date
CN115361957A (zh) 2022-11-18
BR112022017560A2 (pt) 2022-12-27
CA3170915A1 (en) 2021-09-16
AU2021234104A1 (en) 2022-09-29
WO2021180850A1 (en) 2021-09-16
EP4117691A1 (en) 2023-01-18
KR20220152239A (ko) 2022-11-15
US20230172991A1 (en) 2023-06-08

Similar Documents

Publication Publication Date Title
JP2023517641A (ja) 炎症性腸疾患を治療するための方法ｉｉ
US20230165904A1 (en) Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells
JP2023513847A (ja) 慢性移植片対宿主病の治療方法
JP2023517636A (ja) 炎症性腸疾患を治療するための方法ｉ
CN115361958A (zh) 使用间充质谱系前体或干细胞治疗炎症性肺病的方法
US20240207323A1 (en) Method for treating acute respiratory distress syndrome (ards) using mesenchymal lineage precursor or stem cells
US20250032552A1 (en) Method of treating severe graft versus host disease
WO2025046491A1 (en) Third line treatment for gvhd

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240304

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250311

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250605

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250904

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260408